$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Crosslinked, porous polymers for controlled drug delivery 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • C08L-075/00
  • C08G-073/12
  • A61K-009/22
출원번호 US-0523236 (1983-08-15)
발명자 / 주소
  • Mueller, Karl F.
  • Heiber, Sonia J.
출원인 / 주소
  • Ciba-Geigy Corporation
대리인 / 주소
    Hall, Luther A. R.
인용정보 피인용 횟수 : 148  인용 특허 : 6

초록

A controlled-release, drug-delivery composition which comprises (A) a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by weight of

대표청구항

1. A controlled-release, drug-delivery carrier composition which comprises a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by

이 특허에 인용된 특허 (6)

  1. Dobo Janos (Budapest HUX) Takacs Erzsebet (Budapest HUX) Hortobagyi Gyozo (Budapest HUX) Skvorecz nee Hajnoczy Marianne (Budapest HUX) Kolbe Ilona (Budapest HUX) Hoffmann nee Vas Katalin (Budapest HU, Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceut.
  2. Lerk Coenraad F. (Roden NLX), Controlled release composition and process for preparing same.
  3. Mueller Karl F. (New York NY) Kleiner Eduard K. (New York NY), Polysiloxane hydrogels.
  4. Lim Drahoslav (Prague CSX) Coupek Jiri (Prague CSX) Krivakova Miroslava (Prague CSX) Pokorny Svatopluk (Prague CSX), Preparation of hydrophilic material for gel chromatography.
  5. Mueller Karl F. (New York NY) Heiber Sonia J. (Bedford Hills NY) Plankl Walter L. (Yorktown Heights NY), Process for preparing hydrogels as spherical beads of large size.
  6. Mueller Karl F. (New York NY) Good William R. (Yorktown Heights NY), Water-insoluble hydrophilic copolymers.

이 특허를 인용한 특허 (148)

  1. Li, Yun-Long; Rodgers, James D., 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors.
  2. Li, Yun-Long; Rodgers, James D., 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors.
  3. Li, Yun-Long; Rodgers, James D., 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors.
  4. Gotsche, Michael; Kolter, Karl; Sanner, Axel; Angel, Maximilian; Leinenbach, Alfred, APPLICATION OF WATER-SOLUBLE OR WATER-DISPERSIBLE POLYMERIZATES WHICH CONTAIN POLY-ETHER AND WHICH ARE USED AS A COATING AGENT, A BINDING AGENT AND/OR AS A FILM-FORMING AUXILIARY AGENT IN PHARMACEUTI.
  5. Rodgers, James D.; Shepard, Stacey, Azetidine and cyclobutane derivatives as JAK inhibitors.
  6. Rodgers, James D.; Shepard, Stacey, Azetidine and cyclobutane derivatives as JAK inhibitors.
  7. Yao, Wenqing; Burns, David M.; Zhuo, Jincong, Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors.
  8. Yao, Wenqing; Burns, David M; Zhuo, Jincong, Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors.
  9. Yao, Wenqing; Burns, David; Zhuo, Jincong, Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors.
  10. Robinson Joseph R. (Madison WI), Bioadhesive composition and method of treatment therewith.
  11. Robinson Joseph R. (Madison WI), Bioadhesive compositions and methods of treatment therewith.
  12. Kiser, Patrick F.; Thomas, Allen A., Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments.
  13. Ng, Steven Y.; Heller, Jorge, Bioerodible poly (orthoesters) from dioxolane-based diketene acetals.
  14. Ng, Steven Y.; Heller, Jorge, Block copolymers based on poly(ortho esters) containing amine groups.
  15. Joh Yasushi (Yokohama JPX), Compositions having antithrombogenic properties and blood contact medical devices using the same.
  16. Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
  17. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  18. Oshlack Benjamin ; Chasin Mark ; Pedi ; Jr. Frank, Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  19. Oshlack,Benjamin; Chasin,Mark; Pedi, Jr.,Frank, Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  20. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  21. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  22. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  23. Oshlack, Benjamin; Huang, Hua Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  24. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  25. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  26. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  27. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  28. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  29. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  30. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  31. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  32. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  33. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  34. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  35. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  36. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  37. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  38. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  39. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  40. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Controlled release hydrocodone formulations.
  41. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  42. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  43. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  44. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  45. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  46. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  47. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  48. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  49. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  50. Oshlack, Benjamin; Masselink, John K.; Huang, Hua-Pin; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  51. Lipshitz Harold M. (Carlisle MA), Controlled topical application of bioactive reagent.
  52. Bowman, Lyle; Pham, Stephen, Controlled-release ophthalmic vehicles.
  53. Winter, H. Henning; Gappert, Griffin, Crystallization of constrained polymers.
  54. Rodgers, James D.; Shepard, Stacey; Zhu, Wenyu; Shao, Lixin; Glenn, Joseph, Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors.
  55. Rodgers, James D.; Arvanitis, Argyrios G., Cyclohexyl azetidine derivatives as JAK inhibitors.
  56. Brocchini,Stephen J.; Heller,Jorge; Tomlinson,Ryan; Duncan,Ruth; Garrett,Shane; Klee,Marcus M., Degradable polyacetal polymers.
  57. Sanders Lynda M. (Palo Alto CA) Domb Abraham (Brookline MA), Delayed/sustained release of macromolecules.
  58. Bryant Charles P. ; Grisso Bryan A. ; Cantiani Robert,FRX, Dispersant-viscosity improvers for lubricating oil compositions.
  59. Bryant Charles P. ; Grisso Bryan A. ; Cantiani Robert,FRX, Dispersant-viscosity improvers for lubricating oil compositions.
  60. Bryant, Charles P.; Grisso, Bryan A.; Cantiani, Robert, Dispersant-viscosity improvers for lubricating oil compositions.
  61. Sivik Matthew R. ; Bryant Charles P., Dispersant-viscosity improvers for lubricating oil compositions.
  62. Sivik, Matthew R.; Bryant, Charles P., Dispersant-viscosity improvers for lubricating oil compositions.
  63. Schwartz Daniel M. ; Baxter John D. ; Jumper Michele D. ; Scanlan Thomas S., Eye treatments using synthetic thyroid hormone compositions.
  64. Schwartz, Daniel M.; Baxter, John D.; Jumper, Michele D.; Scanlan, Thomas S., Eye treatments using synthetic thyroid hormone compositions.
  65. Schwartz,Daniel M.; Baxter,John D.; Jumper,Michele D.; Scanlan,Thomas S., Eye treatments using synthetic thyroid hormone compositions.
  66. Grassano Alessandro,ITX ; Marchiorri Maurizio,ITX ; Di Toro Mauro,ITX ; Castegini Franco,ITX, Fast dissolving compositions having analgesic activity.
  67. Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase.
  68. Rodgers, James D.; Shepard, Stacey, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors.
  69. Rodgers, James D.; Shepard, Stacey, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors.
  70. Rodgers, James D.; Shepard, Stacey, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors.
  71. Rodgers, James D.; Shepard, Stacey, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors.
  72. Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors.
  73. Rodgers, James D.; Shepard, Stacey, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
  74. Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
  75. Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
  76. Rodgers, James D.; Li, Yun-Long; Shepard, Stacey; Wang, Haisheng, Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors.
  77. Rodgers, James D.; Zhu, Wenyu; Glenn, Joseph, Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors.
  78. Good William R. (Suffern NY) Mikes John (Madison NJ) Sikora Joseph (Wanaque NJ), Hydrogels with increased organic solvent soluble active agent loading capacity, their preparation and the use thereof.
  79. Schmidt, Michael March; Barnes, Thomas M.; Erbe, David V.; Furfine, Eric Steven; Tisdale, Alison, IL-6 antagonists and uses thereof.
  80. Richards, William L.; Ashby, Austin; Ketterer, Matthew; Marshall, Kevin; Harrison, Josh; Mette, Matthew; Richards, Paul; Showalter, Wayne; Cote, Jasmin; Halbert, Phillip C.; Bourgeois, Solene; Metzger, Steven W.; Hance, Ken; Mensack, Meghan; Michel, Carlos; Allers, Elke; Gamage, Dulini; Prisbrey, Landon; Gusyatin, Oleg; Shamsheyeva, Alena; Turng, Ben; Ghusson, Andrew; Reinhardt, Kurt, Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing.
  81. Torgerson Peter M. (Washington Court House OH), Low glass transistion temperature adhesive copolymers for use in hair styling products.
  82. DeFusco Albert A. (Ridgecrest CA) Martin Eugene C. (Ridgecrest CA), Maleimidomethyl-carbonate polyethers.
  83. Prisbrey, Landon; Blackmore, Elise; Hance, Kenneth R.; Metzger, Steven W.; Marshall, Kevin, Membrane-assisted purification.
  84. Polansky Jon R. (Mill Valley CA) Bloom Ernest (Alamo CA) Fauss Donald J. (San Francisco CA), Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division.
  85. Sackler Richard ; Kaiko Robert ; Goldenheim Paul, Method of treating humans with opioid formulations having extended controlled release.
  86. Sackler, Richard; Kaiko, Robert; Goldenheim, Paul, Method of treating humans with opioid formulations having extended controlled release.
  87. Katz Martin A. ; Cheng Chung H. ; Nacht Sergio, Methods and compositions for topical delivery of benzoyl peroxide.
  88. Won Richard ; Katz Martin A. ; Cheng Chung H. ; Nacht Sergio, Methods and compositions for topical delivery of retinoic acid.
  89. Si,Erwin; Bowman,Lyle M., Methods and compositions for treating and inhibiting retinal neovascularization.
  90. Vargas Rincon, Ricardo Alberto; Reiz, Joseph, Methods and compositions particularly for treatment of attention deficit disorder.
  91. Vargas Rincon, Ricardo Alberto; Reiz, Joseph, Methods and compositions particularly for treatment of attention deficit disorder.
  92. Polansky Jon R. (Mill Valley CA) Bloom Ernest (Alamo CA) Fauss Donald J. (San Francisco CA), Methods for the cyto-protection of the trabecular meshwork.
  93. Bowman, Lyle; Hosseini, Kamran, Methods for treating ocular inflammatory diseases.
  94. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of manufacturing oral dosage forms.
  95. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of manufacturing oral formulations.
  96. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of providing analgesia.
  97. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of providing analgesia.
  98. Rodgers, James D.; Shepard, Stacey; Arvanitis, Argyrios G.; Wang, Haisheng; Storace, Louis; Folmer, Beverly; Shao, Lixin; Zhu, Wenyu; Glenn, Joseph, N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors.
  99. Rodgers, James D; Shepard, Stacey; Arvanitis, Argyrios G; Wang, Haisheng; Storace, Louis; Folmer, Beverly; Zhu, Wenyu; Glenn, Joseph; Shao, Lixin, N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors.
  100. Sivik Matthew R. ; Bryant Charles P., Nitrogen containing acrylic copolymers.
  101. Hosseini, Kamran; Bowman, Lyle; Si, Erwin C.; Pham, Stephen, Non-steroidal anti-inflammatory ophthalmic compositions.
  102. Wimmer, Walter; Brogmann, Bianca; Hahn, Udo; Spitzley, Christof, Opioid analgesic.
  103. Chasin Mark ; Oshlack Benjamin ; Pedi ; Jr. Frank, Opioid formulations having extended controlled release.
  104. Chasin Mark ; Oshlack Benjamin ; Pedi ; Jr. Frank, Opioid formulations having extended controlled released.
  105. Oshlack Benjamin ; Chasin Mark, Orally administrable opioid formulations having extended duration of effect.
  106. Oshlack Benjamin ; Chasin Mark, Orally administrable opioid formulations having extended duration of effect.
  107. Oshlack, Benjamin; Chasin, Mark, Orally administrable opioid formulations having extended duration of effect.
  108. Oshlack,Benjamin; Chasin,Mark, Orally administrable opioid formulations having extended duration of effect.
  109. Huang, Taisheng; Xue, Chu-Biao, Piperidin-4-yl azetidine derivatives as JAK1 inhibitors.
  110. Huang, Taisheng; Xue, Chu-Biao; Li, Hui-Yin; Li, Qun, Piperidin-4-yl azetidine derivatives as JAK1 inhibitors.
  111. Huang, Taisheng; Xue, Chu-Biao; Li, Hui-Yin; Li, Qun, Piperidin-4-yl azetidine derivatives as JAK1 inhibitors.
  112. Rodgers, James D.; Shepard, Stacey; Zhu, Wenyu; Shao, Lixin; Glenn, Joseph, Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors.
  113. Cutter Louis A. (Allegheny PA) Ganger Richard A. (Carmel Valley CA) Godfrey John J. (Murrysville PA), Polymer partculates for molding and the like.
  114. Naylor, Andrew; Lewis, Andrew Lester; Illum, Lisbeth, Process for preparing microparticles.
  115. Fauq, Abdul H.; Edwards, Albert O., Process for the synthesis of long-chain fatty acids.
  116. Cao, Ganfeng, Processes and intermediates for making a JAK inhibitor.
  117. Liu, Pingli; Wang, Dengjin; Wu, Yongzhong; Cao, Ganfeng; Xia, Michael, Processes and intermediates for making a JAK inhibitor.
  118. Liu, Pingli; Wang, Dengjin; Wu, Yongzhong; Cao, Ganfeng; Xia, Michael, Processes and intermediates for making a JAK inhibitor.
  119. Zhou, Jiacheng; Wu, Yongzhong; Liu, Pingli, Processes and intermediates for making a JAK inhibitor.
  120. Zhou, Jiacheng; Wu, Yongzhong; Liu, Pingli; Cao, Ganfeng, Processes and intermediates for making a JAK inhibitor.
  121. Rodgers, James D.; Shepard, Stacey; Maduskuie, Thomas P.; Wang, Haisheng; Falahatpisheh, Nikoo; Rafalski, Maria; Arvanitis, Argyrios G.; Storace, Louis; Jalluri, Ravi Kumar, Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
  122. Metzger, Steven W.; Hance, Kenneth Robert, Rapid cell purification systems.
  123. Metzger, Steven W.; Hance, Kenneth Robert, Rapid cell purification systems.
  124. Metzger, Steven W.; Hance, Kenneth Robert, Rapid cell purification systems.
  125. Shamsheyeva, Alena; Howson, David C.; Metzger, Steven W., Rapid determination of microbial growth and antimicrobial susceptibility.
  126. Rodgers, James D.; Li, Hui-Yin, Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
  127. Rodgers, James D.; Li, Hui-Yin, Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
  128. Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
  129. Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
  130. Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
  131. Goldberg, David A.; Howson, David C.; Metzger, Steven W.; Buttry, Daniel A.; Saavedra, Steven Scott, Sensitive and rapid determination of antimicrobial susceptibility.
  132. Oshlack Benjamin ; Chasin Mark ; Pedi ; Jr. Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
  133. Oshlack, Benjamin; Chasin, Mark; Pedi, Jr., Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
  134. Oshlack,Benjamin; Chasin,Mark; Pedi, Jr.,Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
  135. Oshlack Benjamin ; Huang Hua-Pin ; Chasin Mark ; Goldenheim Paul, Stabilized sustained release tramadol formulations.
  136. Oshlack, Benjamin; Huang, Hua-Pin; Chasin, Mark; Goldenheim, Paul, Stabilized sustained release tramadol formulations.
  137. Sung Cynthia (Cambridge MA) Merrill Edward W. (Belmont MA), Surface-active polysiloxanes and drug releasing materials thereof.
  138. Heafield Joanne,GBX ; Knott Trevor John,GBX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Miller Ronald Brown,CHX ; Prater Derek Allan,GBX ; Smith Kevin John,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
  139. Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
  140. Yeleswaram, Krishnaswamy; Parikh, Bhavnish; Modi, Dilip P.; Sheth, Trupti, Sustained release dosage forms for a JAK1 inhibitor.
  141. Ni, Yong; Parikh, Bhavnish; Yeleswaram, Krishnaswamy; Erickson-Viitanen, Susan; Williams, William V., Sustained-release dosage forms of ruxolitinib.
  142. Nonomura Muneo (Osaka JPX) Suzuki Yasuyuki (Osaka JPX) Yamada Masayuki (Hyogo JPX), Sustained-release preparation and production thereof.
  143. Robinson Joseph R., Tissue moisturizing composition and method.
  144. Ribeiro Dos Santos, Isabel; Sournac, Michel, Transdermal device including porous microparticles.
  145. Leopold, Lance Howard; Assad, Albert, Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1.
  146. Robinson Joseph R. ; Bologna William J., Use of polycarboxylic acid polymers to treat vaginal infections.
  147. Seebauer Joseph G. ; Bryant Charles P., Viscosity improvers for lubricating oil compositions.
  148. Seebauer Joseph G. ; Bryant Charles P., Viscosity improvers for lubricating oil-compositions.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로